" /> Uliledlimab - CISMeF





Preferred Label : Uliledlimab;

NCIt synonyms : Anti-CD73 Monoclonal Antibody TJ4309;

NCIt definition : A humanized monoclonal antibody targeting the ectoenzyme 5'-ecto-nucleotidase (cluster of differentiation 73; CD73; 5'-NT; ecto-5'-nucleotidase; NT5E), with potential immunomodulating and antineoplastic activities. Upon administration, uliledlimab targets and binds to CD73 on tumor cells, thereby inhibiting CD73 activity. This prevents CD73-mediated conversion of extracellular adenosine monophosphate (AMP) to adenosine, preventing adenosine-mediated suppression of lymphocyte activity and increasing the activity of cytotoxic T-lymphocytes (CTLs). This also activates macrophages and reduces the activity of both myeloid-derived suppressor cells (MDSCs) and regulatory T-lymphocytes (Tregs). By abrogating the inhibitory effect on the immune system and enhancing the CTL-mediated immune response against cancer cells, tumor cell growth is decreased. CD73, a plasma membrane protein belonging to the 5'-nucleotidase (NTase) family, is upregulated on a number of cancer cell types and catalyzes the conversion of extracellular nucleotides, such as AMP, to membrane-permeable nucleosides, such as adenosine; it plays a key role in adenosine-mediated immunosuppression within the tumor microenvironment (TME).;

UNII : 3OX1DBR75G;

CAS number : 2378407-27-1;

Molecule name : TJD5; TJ 4309; TJ-4309; TJ-004309; TJ 004309;

NCI Metathesaurus CUI : CL951040;

Details


You can consult :


Nous contacter.
09/05/2025


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.